Search results
He threatened Marjorie Taylor Greene amid a mental health crisis. Then came the consequences.
New Hampshire Union Leader· 8 hours agoThe night he made the threat, Joe Morelli was exactly where he is now two years later, on his couch....
Schizoid vs. Schizotypal Personality Disorders
Verywell Mind via Yahoo News· 5 days agoPrevalence and Causes...risk of developing schizotypal personality disorder might be higher if you have a relative with a psychotic disorder like...
Anosognosia: Everything You Need to Know
Verywell Health via Yahoo News· 5 days agoSomeone living with anosognosia may not be aware they have an illness and need treatment. They might doubt their diagnosis, attribute signs and symptoms...
Understanding Benzodiazepines and How They Work
Verywell Health via Yahoo News· 4 days agoBenzodiazepines (also known as benzos) are a class of medications used to treat anxiety disorders, seizures, insomnia, and other health conditions. While...
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its...
Morningstar· 6 days agoThe Company’s plan to conduct this trial using a 120 mcg dose is based on feedback received from the U.S. Food and Drug Administration (FDA...
Avoidance Predicts Worse Long-term Outcomes in OCD
Medscape· 6 days agoBehavioral avoidance could limit the long-term of a widely used treatment for obsessive compulsive disorder, a new analysis shows.
Florida clinic plans to treat 10,000 Alzheimer’s patients a year. Look at what’s coming
Miami Herald via Yahoo News· 3 days agoLeqembi is “clearly only one part of what will need to be a much broader treatment program in the...
Youth center victim seeking $1.5M for treatment
The Eagle-Tribune· 1 day agoA medical expert called to testify for David Meehan in his trailblazing lawsuit against the state testified Thursday he will need life-long Post...
New Jersey Intensive Outpatient Program For Mental Health Disorders Updated
Digital Journal· 3 days agoThis includes ADD/ADHD, anxiety, bipolar disorder, depression, OCD, personality disorders, PTSD, schizophrenia, substance abuse
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of...
WWTI Watertown· 4 days agoAlkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with ...
